Reducing attrition rates in drug discovery is critical to increasing the success of the drug discovery and development process. Identifying problems associated with compounds as early as possible allows precious resources to be directed towards chemistries that are much more likely to advance to candidate selection and on to clinical evaluation. Apredica and Gentronix have come together to provide a suite of predictive toxicology in vitro services to help you get the results you need quickly, accurately and cost effectively.
Predictive Toxicology:
The cost of drug discovery continues to rise while the output of new NDAs continues to fall. Consequently it has never been more important to address attrition rates in drug discovery and development. Early indication of toxicity in a molecule or lead family means that discovery resources can be directed either at other chemical series if these are available or towards ‘breeding’ out undesirable properties. Gentronix and Apredica have come together, building on the strengths of each to provide a cost effective package of in vitro toxicology services that meet the needs of Pharmaceutical and Biotechnology companies alike.
Whether you are looking to ease internal bottlenecks in your own toxicology and ADME functions or have compounds to progress but no internal resource in expert areas: we have the expertise and resources to help you get your compounds where they need to be. Combining specialist expertise in genotoxicity and GreenScreen HC proprietary early screening technology from Gentronix with Apredica’s breadth of services in ADME-Tox gives you the right mix of specialists to deliver fast, comprehensive results to support your discovery and development needs.
We present a range of services from screening and preliminary evaluation packages to full in vitro toxicology profiling that can be further tailored.
Contact us to discuss how we can help you advance compounds to be your next generation of clinical candidates.
Testing Packages:
Click here to go to the downloads page for individual flyers on each of these assays...
Screening Profile
- Mammalian Cytotoxicity [3 concentrations]
- Mitochondrial Toxicity [3 concentrations]
- Phospholipidosis [3 concentrations]
- hERG [2 concentrations]
- Reactive Metabolites [streamlined]
- CYP Interaction [6 P450s; 2 concentrations]
- CaCo-2 [ bi-directional]
- GreenScreen HC [3 concentrations]
- Haemolysis [3 concentrations]
(12 compound minimum) |
Primary Profile
- Mammalian Cytotoxicity [9 concentrations]
- Mitochondrial Toxicity [9 concentrations]
- Phospholipidosis [9 concentrations]
- hERG [6 concentrations in duplicate]
- Reactive Metabolites
- GreenScreen HC [9 concentrations]
- GreenScreen HC S9 [9 concentrations]
|
Full Profile
- Mammalian Cytotoxicity [9 concentrations]
- Mitochondrial Toxicity [9 concentrations]
- Phospholipidosis [9 concentrations]
- hERG [6 concentrations in duplicate]
- Reactive Metabolites
- CYP Interaction [5 P450s; 2 concentration screen 2 IC-50]
- CaCo-2 [bi-directional /- verapamil]
- GreenScreen HC [9 concentrations]
- GreenScreen HC S9 [9 concentrations]
- Haemolysis [9 concentrations]
|
